Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EPS (Weighted Average and Diluted) (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.29 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 108.29% to -$0.29 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.78, a 70.0% increase, with the full-year FY2025 number at $2.57, up 122.52% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.29 in Q1 2026 for Atara Biotherapeutics, up from -$0.36 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.5 in Q1 2025 to a low of -$16.91 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.73 (2022), compared with a mean of -$3.48.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 9494.44% in 2023 and later surged 161.95% in 2025.
  • Atara Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$0.73 in 2022, then crashed by 1806.85% to -$13.92 in 2023, then soared by 99.5% to -$0.07 in 2024, then crashed by 414.29% to -$0.36 in 2025, then increased by 19.44% to -$0.29 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.29 (Q1 2026), -$0.36 (Q4 2025), and -$0.32 (Q3 2025) per Business Quant data.